medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2021, Number 3

<< Back Next >>

VacciMonitor 2021; 30 (3)

Nimotuzumab combined with GEMOX chemotherapy regimen in patients with advanced pancreatic cance

Lima-Pérez M, Soriano-García JL, González-Meisozo M, Rodríguez-Barrios R, Vals-Machado Y, Domínguez-Álvarez C, Morales-Morgado D, Fleites-Calvo V, Ramón-Concepción I, Batista-Albuerne N

Language: Spanish
References: 21
Page: 133-144
PDF size: 392.73 Kb.


ABSTRACT

A retrospective and observational study was carried out in patients with advanced pancreatic adenocarcinoma, treated with Nimotuzumab combined with a GEMOX chemotherapy scheme, in the Clinical Oncology Service at the Ameijeiras Hospital, between 2013 and 2019 (n =118), whose objective was to evaluate the response to the treatment and overall survival according to clinical, histopathological and treatment variables. The chi-square method was used for the association of variables. Overall survival was evaluated by the Kaplan Meier method and the Log-Rank and Breslow test for the comparison of the curves, with p <0.05. The disease control rate was 44.9. The median survival was 13.8 months (95% CI: 11.7-15.8). The statistically significant variables associated with greater response to treatment and survival were: no smoking habits; platelet-lymphocyte index below 200; T2-T3 primary tumors, predominantly located in the pancreatic head; no presence of metastases at diagnosis and greater than six doses of chemotherapy and Nimotuzumab. Patients classified as underweight and low serum albumin had worse survival (p <0.05). Second-line chemotherapy was performed in 42 patients and it was obtained SV of 17.4 months (95% CI: 13.5-21.4). Toxicities classified as grade 3-4 were reported in 27 patients (22.9%); the most frequently observed were: neuropathy (14.4%), neutropenia (10.2%) and thrombopenia (9.3%). Under clinical practice conditions, Nimotuzumab combined with GEMOX chemotherapy obtained optimal disease control and survival rates with a good safety profile.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424. doi: https://10.3322/caac.21492.

  2. Ministerio de Salud Pública de Cuba. Anuario Estadístico de Salud 2019. La Habana: Ministerio de Salud Pública; 2020. Disponible en: https://files.sld.cu/bvscuba/files/2020/05/AnuarioElectrónico-Español-2019-ed-2020.pdf.

  3. Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev Anticancer Ther. 2018;18(3):295-304. doi: https://10.1080/14737140.2018.1428093.

  4. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73-85. doi: https://10.1016/S0140-6736(16)00141-0.

  5. Jin SF, Fan ZK, Pan L, Jin LM. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials. Hepatobiliary Pancreat Dis Int. 2017;16(3):236-44. doi: https://10.1016/s1499-3872(17)60022-5.

  6. Lee S, Heinrich EL, Lu J, Lee W, Choi AH, Luu C, et al. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Pancreas. 2016;45(2):286-92. doi: https://10.1097/MPA.0000000000000379.

  7. Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wild-type patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017;28(10):2429-35. doi: https://10.1093/annonc/mdx343.

  8. Su D, Jiao SC, Wang LJ, Shi WW, Long YY, Li J, et al. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol. 2014;35(3):2313-8. doi: https://10.1007/s13277-013-1306-x.

  9. Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol. 2016;22(46):10124-30. doi: https://10.3748/wjg.v22.i46.10124.

  10. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-16. doi: https://10.1200/JCO.2005.06.023.

  11. Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol. 2011;4:11. doi: https://10.1186/1756-8722-4-11.

  12. Giuliani J, Bonetti A. The gemcitabine and oxaliplatin (GEMOX) for advanced pancreatic cancer: the reports of my death have been greatly exaggerated? Recenti Prog Med. 2017;108(12):521-7. doi: https://10.1701/2829.28584.

  13. Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 2018;45(1-2):18-26. doi: https://10.1053/j.seminoncol.2018.04.008.

  14. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012;30(3):1138-43. doi: https://10.1007/s10637-010-9619-8.

  15. Principe DR, Narbutis M, Kumar S, Park A, Viswakarma N, Dorman MJ, et al. Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy. Cancer Res. 2020; 80(15):3101-15. doi: https://10.1158/0008-5472.CAN-19-2959.

  16. Stojanovska V, Prakash M, McQuade R, Fraser S, Apostolopoulos V, Sakkal S, et al. Oxaliplatin treatment alters systemic immune responses. Biomed Res Int. 2019;2019:4650695. doi: https://10.1155/2019/4650695.

  17. Philip PA, Benedetti J, Corless CL, Wong R, O Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605-10. doi: https://10.1200/JCO.2009.25.7550.

  18. Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, et al. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-72. doi: https://10.2147/DDDT.S105442.

  19. Kim GP, Parisi MF, Patel MB, Pelletier CL, Belk KW. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. Expert Rev Clin Pharmacol. 2017;10(5):559-5. doi: https://10.1080/17512433.2017.1302330.

  20. Zhou Y, Cheng S, Fathy AH, Qian H, Zhao Y. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther. 2018;11:1899-08. doi: https://10.2147/OTT.S154162.

  21. Piciucchi M, Stigliano S, Archibugi L, Zerboni G, Signoretti M, Barucca V, et al. The Neutrophil/Lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. Int J Mol Sci. 2017;18(4):730. doi: https://10.3390/ijms18040730.




2020     |     www.medigraphic.com